At the time of writing, Integra Lifesciences Holdings Corp [IART] stock is trading at $17.35, up 3.95%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IART shares have gain 10.72% over the last week, with a monthly amount drifted -20.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Integra Lifesciences Holdings Corp [NASDAQ: IART] stock has seen the most recent analyst activity on March 31, 2025, when Argus upgraded its rating to a Buy. Previously, Morgan Stanley started tracking the stock with Underweight rating on December 02, 2024, and set its price target to $20. On October 07, 2024, upgrade upgraded it’s rating to Neutral. Citigroup downgraded its rating to a Sell and decreased its price target to $23 on July 30, 2024. BTIG Research downgraded its rating to a Sell but $22 remained the price target by the analyst firm on July 30, 2024. Wells Fargo downgraded its rating to Equal Weight for this stock on May 07, 2024, and downed its price target to $25. In a note dated May 07, 2024, Oppenheimer downgraded an Perform rating on this stock.
For the past year, the stock price of Integra Lifesciences Holdings Corp fluctuated between $14.45 and $32.66. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Integra Lifesciences Holdings Corp [NASDAQ: IART] shares were valued at $17.35 at the most recent close of the market. An investor can expect a potential return of 147.84% based on the average IART price forecast.
Analyzing the IART fundamentals
According to Integra Lifesciences Holdings Corp [NASDAQ:IART], the company’s sales were 1.61B for trailing twelve months, which represents an 11.49% jump. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is 0.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.66 points at the first support level, and at 15.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.79, and for the 2nd resistance point, it is at 18.23.
Ratios To Look Out For
It is important to note that Integra Lifesciences Holdings Corp [NASDAQ:IART] has a current ratio of 1.17. Further, the Quick Ratio stands at 0.71, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 0.83, the price to book ratio is 0.87.
Transactions by insiders
Recent insider trading involved Schwartz Eric, EVP, Chief Legal Officer & Sec, that happened on Dec 03 ’24 when 4070.0 shares were sold. Officer, Schwartz Eric completed a deal on Dec 03 ’24 to buy 4070.0 shares. Meanwhile, EVP & President, CSS McBreen Michael J. sold 1700.0 shares on Dec 02 ’24.
